Surgical and medical treatment of clear cell ovarian cancer, results from the multicenter italian trials in ovarian cancer (MITO) 9 retrospective study

International Journal of Gynecological Cancer

Volumn 21, Issue 6, 2011, Pages 1063-1070

  Magazzino, Francescapaola ^b   Katsaros, Dionyssios ^c   Ottaiano, Alessandro ^a   Gadducci, Angiolo ^d   Pisano, Carmela ^a   Sorio, Roberto ^e   Rabaiotti, Emanuela ^f   Scambia, Giovanni ^g   Cormio, Gennaro ^b   Scarampi, Luca ^c   Greggi, Stefano ^a   Savarese, Antonella ^h   Marinaccio, Marco ^b   Scollo, Paolo ⁱ   Pignata, Sandro ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b POLICLINICO   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e Istituto Nazionale Tumori Aviano   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^h REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

ⁱ CANNIZZARO HOSPITAL   (Italy)

Author keywords

Chemotherapy; Clear cell; Lymphadenectomy; Ovarian carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLEAR CELL OVARY CARCINOMA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FEMALE FERTILITY; HISTOPATHOLOGY; HUMAN; ITALY; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STANDARD; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ITALY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 83055178968     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318218f270     Document Type: Article

References (25)

1. Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 1991;9:1138Y1150.
2. Jenison EL, Montag AG, Griffiths CT, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol. 1989;32:65Y71. (Pubitemid 19029870)
3. du Bois A, QuinnM, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16:viii7Yviii12. (Pubitemid 41631227)
4. Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cells ovarian cancers. Gynecol Oncol. 2008;109:370Y376.
5. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996;60:412Y417. (Pubitemid 26077628)
6. Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2006;102:285Y291. (Pubitemid 44041640)
7. Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors of lymph node metastasis in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:1238Y1244. (Pubitemid 350077354)
8. Maggioni A, Benedetti Panici P, Dell'Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer. 2006;95:699Y704. (Pubitemid 44373484)
9. Ho CM, Chien TY, Shih BY, et al. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol. 2003;88:394Y399.
10. Chan JK, Munro EG, Cheung MK, et al. Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol. 2007;109:12Y19. (Pubitemid 46043192)
11. Suzuki S, Kajiyama H, Shibata K, et al. Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cells carcinoma patients? Ann Oncol. 2008;19:1284Y1287. (Pubitemid 351911958)
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205Y216. (Pubitemid 30099779)
13. Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996;14:1545Y1551. (Pubitemid 26134212)
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457Y481.
15. International Collaborative Ovarian Neoplasm 1 (ICON 1) and European Organisation for Research and Treatment of Cancer CollaboratorsVAdjuvant ChemoTherapy In Ovarian Neoplasm (EORTC-ACTION). International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm Trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95:105Y112.
16. Utsunomya H, Akahira J, Tanno S, et al. Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer. 2006;16:52Y56.
17. du Bois A, Reuss A, Harter P, et al. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol. 2010;28:1733Y1739.
18. Benedetti Panici P, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97:560Y566. (Pubitemid 40723783)
19. Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer. 2006;94:1369Y1374. (Pubitemid 43772268)
20. Takano M, Sugiyama T, Yaegashi N, et al. The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study. Int J Gynecol Cancer. 2009;19:1353Y1357.
21. Ho CM, Huang YJ, Chen TC, et al. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinumYbased chemotherapy in pure-type advanced disease. Gynecol Oncol. 2004;94:197Y203.
22. Cloven NG, Kyshtoobayeva A, Burger RA, et al. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol. 2004;92:160Y166. (Pubitemid 38147385)
23. Otsuka J, Okuda T, Sekizawa A, et al. K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma. Med Electron Microsc. 2004;37:188Y192. (Pubitemid 40576037)
24. Aoki D, Oda Y, Hattori S, et al. Overexpression of class III beta tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin Cancer Res. 2009;15:1473Y1480.
25. Rauh-Hain JA, Penson RT. Potential benefit of sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. Int J Gynecol Cancer. 2008;18:934Y936.